Sign in

Private company

Evelo Biosciences, Inc.

Evelo Biosciences, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Foxboro, Massachusetts.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersFoxboro, Massachusetts1
  • Incorporated inDE2
  • Business address124 Washington Street, Suite 101, Foxboro, Ma 020352
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34567-$108.5M in 2022+733% since 2016
-$150.0M-$100.0M-$50.0M02016: -$13.0M-$13.0M20162017: -$27.5M-$27.5M2017+111%2018: -$58.1M-$58.1M2018+111%2019: -$86.4M-$86.4M2019+49%2020: -$91.9M-$91.9M2020+6%2021: -$115.4M-$115.4M2021+26%2022: -$108.5M-$108.5M2022−6%
Net income34567-$114.5M in 2022+759% since 2016
-$150.0M-$100.0M-$50.0M02016: -$13.3M-$13.3M20162017: -$28.0M-$28.0M2017+110%2018: -$56.9M-$56.9M2018+103%2019: -$85.5M-$85.5M2019+50%2020: -$93.7M-$93.7M2020+10%2021: -$122.2M-$122.2M2021+30%2022: -$114.5M-$114.5M2022−6%
Fiscal year20162017201820192020202120222023
Research and development$9.1M3$20.0M4$39.9M4$63.1M5$69.6M6$83.6M7$78.6M7
Operating expenses$115.4M7$108.5M7
Operating income-$13.0M3-$27.5M4-$58.1M4-$86.4M5-$91.9M6-$115.4M7-$108.5M7
Income before tax-$121.7M7-$113.6M7
Income tax$04$04$190.0K5$409.0K6$428.0K7$930.0K7
Net income-$13.3M3-$28.0M4-$56.9M4-$85.5M5-$93.7M6-$122.2M7-$114.5M7
Earnings per share-$2.376-$2.317-$1.317
Earnings per share (diluted)-$2.376-$2.317-$1.317
Shares (weighted, basic)52.9M shares787.2M shares7
Shares (weighted, diluted)52.9M shares787.2M shares7

Compare Evelo Biosciences, Inc. with another company

Corporate structure

Evelo Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Evelo Biosciences, Inc.

  • FMR LLC Filed SC 13G/A on Evelo Biosciences, Inc., latest Dec 11, 2023 (7 filings since Feb 9, 2022)
  • HarbourVest Partners L.P. Filed SC 13G on Evelo Biosciences, Inc., latest Jul 21, 2023 (2 filings since Feb 14, 2023)
  • Horizon Technology Finance Corp Filed SC 13G on Evelo Biosciences, Inc., latest Jul 21, 2023
  • Flagship Ventures Fund V, L.P. Filed SC 13D/A on Evelo Biosciences, Inc., latest Jul 13, 2023 (2 filings since Jun 1, 2022)
  • Finance Dnca Filed SC 13D/A on Evelo Biosciences, Inc., latest Feb 21, 2023 (4 filings since Dec 28, 2021)
  • Credit Suisse Filed SC 13G/A on Evelo Biosciences, Inc., latest Feb 2, 2023 (2 filings since Feb 14, 2022)
  • Evelo Biosciences, Inc. Foxboro, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Evelo Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$14.2M7 Dec 31, 2022$14.3M7 Dec 31, 2021−0.6%
Accumulated depreciation$9.3M7 Dec 31, 2022$7.6M7 Dec 31, 2021+22.3%
Property and equipment, net$4.8M7 Dec 31, 2022$6.6M7 Dec 31, 2021−26.9%
Operating-lease assets (leased space)$6.9M7 Dec 31, 2022$8.9M7 Dec 31, 2021−22.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$47.9M7 Dec 31, 2022$68.4M7 Dec 31, 2021−30.0%

Leadership

Who has led Evelo Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Simba Gill2018–2023

President

  1. Simba Gill2018–2023
  2. Mark Bodmer2019–2023

Chief financial officer

  1. Luca Scavo2021–2022
  2. Marella Thorell2022–2023
20202025
Board members and other officers (22)

Timeline

  1. Jan 26, 20248-K Shareholder vote35
  2. Dec 4, 20238-K Listing notice or transfer36
  3. Nov 21, 20238-K Executive or director change; Other events37
  4. Oct 27, 20238-K Entered a material agreement38
  5. Oct 17, 20238-K Other events39
  6. Aug 21, 20238-K Executive or director change; Other events40
  7. Aug 14, 20238-K Results of operations41
  8. Jul 20, 20238-K Entered a material agreement; Ended a material agreement42
  9. Jul 12, 20238-K Entered a material agreement; Regulation FD disclosure43
  10. Jul 10, 20238-K Entered a material agreement; Unregistered sale of shares; Executive or director change44
  11. Jul 7, 20238-K Other events45
  12. Jun 29, 20238-K Bylaws or fiscal year changed46
  13. May 8, 2018New chief executive Simba Gill becomes CEO10

Calendar

When it reported results

  1. Aug 14, 2023Reported quarterly or annual results41
  2. Mar 16, 2023Reported quarterly or annual results47
  3. Nov 15, 2022Reported quarterly or annual results48
  4. Aug 11, 2022Reported quarterly or annual results49
  5. May 12, 2022Reported quarterly or annual results50
  6. Mar 24, 2022Reported quarterly or annual results51
  7. Oct 28, 2021Reported quarterly or annual results52

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

178 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 42 major events, 88 insider forms, 18 large holders, 20 other. The latest 20:

  1. Mar 8, 2024EFFECT EDGAR
  2. Jan 26, 202415-12G EDGAR
  3. Jan 26, 2024S-8 POS EDGAR
  4. Jan 26, 2024S-8 POS EDGAR
  5. Jan 26, 2024POS AM EDGAR
  6. Jan 26, 20248-K EDGAR
  7. Dec 12, 2023DEFA14A EDGAR
  8. Dec 12, 2023DEF 14A EDGAR
  9. Dec 11, 2023SC 13G/A EDGAR
  10. Dec 4, 20238-K EDGAR
  11. Dec 1, 2023PRE 14A EDGAR
  12. Nov 21, 20238-K EDGAR
  13. Nov 13, 2023SC 13G/A EDGAR
  14. Nov 9, 202310-Q EDGAR
  15. Nov 8, 20234 EDGAR
  16. Nov 8, 20234 EDGAR
  17. Nov 8, 20234 EDGAR
  18. Nov 8, 20234 EDGAR
  19. Nov 3, 20234 EDGAR
  20. Nov 3, 20234 EDGAR

The 178 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 5 buys and 18 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 8, 2023Bodmer MarkCSO, President of R&DSale3,163$0.33$1.0KForm 4
Nov 8, 2023McHale DuncanChief Medical OfficerSale3,103$0.33$1.0KForm 4
Nov 8, 2023GILL SIMBAPresident & CEOSale172$0.33$57Form 4
Nov 8, 2023Thorell MarellaChief Financial OfficerSale1,811$0.33$598Form 4
Nov 2, 2023Bodmer MarkCSO, President of R&DSale6,854$0.33$2.3KForm 4
Nov 2, 2023McHale DuncanChief Medical OfficerSale6,854$0.33$2.3KForm 4
Nov 2, 2023Thorell MarellaChief Financial OfficerSale3,999$0.33$1.3KForm 4
Sep 28, 2023GILL SIMBAPresident & CEOSale1,996$3.94$7.9KForm 4
Aug 8, 2023Bodmer MarkCSO, President of R&DSale3,128$9.51$29.7KForm 4
Aug 8, 2023GILL SIMBAPresident & CEOSale342$9.51$3.3KForm 4
Aug 8, 2023McHale DuncanChief Medical OfficerSale3,434$9.51$32.7KForm 4
Aug 8, 2023Thorell MarellaChief Financial OfficerSale2,004$9.51$19.1KForm 4
Jul 11, 2023Flagship Ventures Fund IV General Partner LLC10% ownerBuy5,411,255$2.31$12.5MForm 4
May 23, 2023Bodmer MarkCSO, President of R&DSale22,571$0.14$3.2KForm 4
May 8, 2023McHale DuncanChief Medical OfficerSale66,730$0.13$8.7KForm 4
May 8, 2023Bodmer MarkCSO, President of R&DSale68,014$0.13$8.8KForm 4
May 8, 2023Thorell MarellaChief Financial OfficerSale38,531$0.13$5.0KForm 4
May 8, 2023GILL SIMBAPresident & CEOSale3,537$0.13$460Form 4
Jan 23, 2023CARRIERE STEPHEN JPrincipal Accounting OfficerSale151$1.06$160Form 4
May 27, 2022McHale DuncanChief Medical OfficerBuy34,246$1.46$50.0KForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Evelo Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREvelo Biosciences, Inc.1
  • CIK0001694665
  • Employer ID (EIN)46-55945271
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address124 Washington Street, Suite 101, Foxboro, MA 020351
  • Phone617-577-03001
  • Shares outstanding18,930,960 as of Nov 6, 20239
  • Public float$119.9M as of Jun 30, 20227
  • On EDGAR sinceJan 18, 20171
  • Filings369 in all: 4 (135), 8-K (84), 3 (33), 10-Q (18), SC 13G/A (13), SC 13G (8), 424B5 (7), CORRESP (7)1
    All 35 form types

    SC 13D/A (7), DEF 14A (6), 10-K (5), DEFA14A (5), EFFECT (5), UPLOAD (4), CT ORDER (3), S-3 (3), 4/A (2), D (2), D/A (2), PRE 14A (2), S-8 (2), S-8 POS (2), SC 13D (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), POS AM (1), S-1 (1), S-1/A (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2023
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Dec 12, 2023
    Latest 8-K (8-K) Jan 26, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58